Omar De León-Vélez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Omar De León-Vélez has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Vázquez-Medina
Department of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, PR 00931, USA
1 shared publication - Alondra Vélez-Cabrera
Department of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, PR 00931, USA
1 shared publication - Amanda Marrero-Sánchez
Department of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, PR 00931, USA
1 shared publication - Andrea N. Maser-Figueroa
Department of Chemistry, University of Puerto Rico-Río Piedras Campus, San Juan 00925, Puerto Rico
1 shared publication - Arthur D. Tinoco
Department of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, United States
1 shared publication - Christopher Nieves-Escobar
Department of Chemistry, University of Puerto Rico, Humacao Campus, Humacao, PR 00792, USA
1 shared publication
Latest Publications
- Open Access
- 16 November 2021
- Published by MDPI AG in Inorganics
- Vol. 9 (11) , 83
Cytochrome c: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug
The heme protein cytochrome c (Cyt c) plays pivotal roles in cellular life and death processes. In the respiratory chain of mitochondria, it serves as an electron transfer protein, contributing to the proliferation of healthy cells. In the cell cytoplasm, it activates intrinsic apoptosis to terminate damaged cells. Insight into these mechanisms and the associated physicochemical properties and biomolecular interactions of Cyt c informs on the anticancer therapeutic potential of the protein, especially in its ability to subvert the current limitations of small molecule-based chemotherapy. In this review, we explore the development of Cyt c as an anticancer drug by identifying cancer types that would be receptive to the cytotoxicity of the protein and factors that can be finetuned to enhance its apoptotic potency. To this end, some information is obtained by characterizing known drugs that operate, in part, by triggering Cyt c induced apoptosis. The application of different smart drug delivery systems is surveyed to highlight important features for maintaining Cyt c stability and activity and improving its specificity for cancer cells and high drug payload release while recognizing the continuing limitations. This work serves to elucidate on the optimization of the strategies to translate Cyt c to the clinical market.
- 16 November 2021
- Published by MDPI AG in Inorganics
- Vol. 9 (11) , 83
Open AccessCytochrome c: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug
The heme protein cytochrome c (Cyt c) plays pivotal roles in cellular life and death processes. In the respiratory chain of mitochondria, it serves as an electron transfer protein, contributing to the proliferation of healthy cells. In the cell cytoplasm, it activates intrinsic apoptosis to terminate damaged cells. Insight into these mechanisms and the associated physicochemical properties and biomolecular interactions of Cyt c informs on the anticancer therapeutic potential of the protein, especially in its ability to subvert the current limitations of small molecule-based chemotherapy. In this review, we explore the development of Cyt c as an anticancer drug by identifying cancer types that would be receptive to the cytotoxicity of the protein and factors that can be finetuned to enhance its apoptotic potency. To this end, some information is obtained by characterizing known drugs that operate, in part, by triggering Cyt c induced apoptosis. The application of different smart drug delivery systems is surveyed to highlight important features for maintaining Cyt c stability and activity and improving its specificity for cancer cells and high drug payload release while recognizing the continuing limitations. This work serves to elucidate on the optimization of the strategies to translate Cyt c to the clinical market.